Initially in the phases 1 and 2 trial, 10 mg SGM-101 (dye-targeted against CEA) was injected 4 days prior to the surgical procedure and was able to detect the primary colonic tumor along with the metastatic deposit in the liver.20 Here, CEACAM5 is linked to colonic neoplasm.